Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SK-BR-3 Neratinib
0.031623
EGFR/HER2
RTK
 0.0194 0.21796
PDXHCI002 Tivantinib
1.0
MET
RTK
 -0.3731 0.60360
SK-BR-3 Neratinib
0.1
EGFR/HER2
RTK
 -0.0389 0.24447
SK-BR-3 Neratinib
0.31623
EGFR/HER2
RTK
 -0.1447 0.30230
PDXHCI002 Tivantinib
0.01
MET
RTK
 1.0723 0.00111
SK-BR-3 Neratinib
1.0
EGFR/HER2
RTK
 -0.2514 0.36911
MCF 10A Cediranib
0.031623
VEGFR/cKIT
RTK
 1.0136 0.00006
SK-BR-3 Neratinib
3.1623
EGFR/HER2
RTK
 -0.2530 0.36589
PDXHCI002 Tivantinib
0.031623
MET
RTK
 1.0374 0.01073
PDXHCI002 Neratinib
0.31623
EGFR/HER2
RTK
 0.3928 0.01351
PDXHCI002 Neratinib
1.0
EGFR/HER2
RTK
 0.1846 0.05265
SK-BR-3 Tivantinib
0.0031623
MET
RTK
 1.0607 0.00171
PDXHCI002 Ceritinib
10.0
ALK
RTK
 -0.6341 0.73056
PDXHCI002 Neratinib
0.031623
EGFR/HER2
RTK
 0.6460 -0.00351
SK-BR-3 Tivantinib
0.01
MET
RTK
 1.0436 0.00173
SK-BR-3 Tivantinib
0.031623
MET
RTK
 1.0714 0.00950
MCF 10A Cediranib
1.0
VEGFR/cKIT
RTK
 1.0068 0.00027
SK-BR-3 Tivantinib
0.1
MET
RTK
 0.8779 0.04583
SK-BR-3 Tivantinib
0.31623
MET
RTK
 0.4015 0.18097
PDXHCI002 Ceritinib
0.31623
ALK
RTK
 0.5616 0.00577
PDXHCI002 Ceritinib
3.1623
ALK
RTK
 -0.6054 0.72078
MCF 10A Cediranib
3.1623
VEGFR/cKIT
RTK
 0.9680 -0.00217
SK-BR-3 Tivantinib
1.0
MET
RTK
 -0.3029 0.52635
SK-BR-3 Tivantinib
3.1623
MET
RTK
 -0.3294 0.54882
MCF 10A Cediranib
10.0
VEGFR/cKIT
RTK
 0.4781 0.01325